CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 66 enrolled
Drug / intervention
PrEP-001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03220048
NCT03220048Phase 2Completed
CompareCT.gov

A Phase II, Repeated Dose, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Healthy Subjects Subsequently Challenged With Influenza A/Perth/16/2009 (H3N2) Virus

Hvivo·interventional·Posted Jul 18, 2017·Updated Nov 12, 2019

In Brief

A Phase 2 clinical trial evaluating PrEP-001 and Placebo Comparator for Influenza A H3N2. Completed, enrolled 66 participants across 1 site.

Detailed Summary

Phase 2 study, looking at the prophylactic efficacy, safety and tolerability to a repeated nasal dose of study drug after being infected with Influenza A/Perth/16/2009 (H3N2) virus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza A H3N2
CountriesUnited Kingdom
CollaboratorsPrep Biopharm Limited

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 18, 2017
Enrollment StartSep 16, 2015
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.0 years ago

Interventions

PrEP-001drug

Placebo Comparatorother